Metformin and Atorvastatin Synergistically Protect the Liver in Type 2 Diabetes with Hyperlipidemia
Abstract Number: 1496-P
Authors: PAULO MATAFOME, BRUNO ALMEIDA, TERESA LOURO, ELSA NUNES, LISA RODRIGUES, JOANA CRISÓSTOMO, CARMEN AMARAL, PEDRO MONTEIRO, AUGUSTA CIPRIANO, RAQUEL SEIÇA
Institutions: Coimbra, Portugal
Results: Liver diseases are linked with dyslipidemia, inflammation and oxidative stress, which are currently observed in type 2 diabetic patients. However, the pathophysiology of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes with hyperlipidemia is not fully understood, as well as the utility of the commonly prescribed anti-diabetic and lipid-lowering drugs in improving liver injury markers. The hepatic complications of type 2 diabetes with hyperlipidemia were tested using the genetic type 2 diabetic Goto-Kakizaki rats feed with a high-fat diet. The effects of atorvastatin and metformin, isolated and in association, in systemic and hepatic inflammatory and oxidative stress markers were then assessed. Rats were feed with standard (SD) or high-fat diet (HD): high-fat feed rats were treated with metformin (HDM), atorvastatin (HDA) or metformin plus atorvastatin (HDMA) during one month. High-fat diet aggravated the overall metabolic state and the hepatic markers of injury. All treatments, isolated or in combination, improved fasting glycemia, insulin resistance and free fatty acid levels; however association treatment significantly improved C-Reactive Protein (CRP), Adiponectin, liver Tumour Necrosis Factor-a (TNF-a) and Interleukin-6 (IL-6), systemic and hepatic oxidative stress in relation to HD, HDM and HDA. These observations were correlated with significant decrease of portal inflammation in HDMA group. Our data provides evidence of a synergistic action of atorvastatin and metformin in improving liver injury in type 2 diabetes with hyperlipidemia.